Nav: Home

Anakinra does not seem to improve fatigue severity in women with chronic fatigue syndrome

March 06, 2017

1. Anakinra does not improve fatigue severity in women with chronic fatigue syndrome

URL goes live when the embargo lifts

The anti-inflammatory biologic drug anakinra (interleukin-1 receptor antagonist) does not reduce fatigue severity in women with chronic fatigue syndrome (CFS). The findings of a randomized, placebo-controlled trial are published in Annals of Internal Medicine.

CFS is characterized by severe, persistent, and disabling fatigue. In order to fulfill the Centers for Disease Control and Prevention (CDC) criteria for CFS, patients have to report at least four of eight accompanying symptoms in addition to fatigue (headache, muscle plain, etc.). Interleukin-1 (IL-1), a pro-inflammatory cytokine, has been associated with CFS in some studies. There is extensive experience with blocking IL-1 in a variety of diseases with the IL-1 receptor antagonist anakinra. Several studies in inflammatory and non-inflammatory illnesses have assessed the effect of IL-1 inhibition on fatigue severity, and most have found positive effects of this intervention.

Researchers from Radboud University Medical Centre in the Netherlands conducted a randomized, placebo-controlled trial to evaluate the effects of anakinra injections versus placebo on fatigue severity in patients with CFS. Since CFS typically affects women, the researchers included only female patients to investigate a homogeneous group. Fifty women with severe fatigue leading to functional impairment were randomly assigned to receive daily anakinra injections (100 mg) or placebo for 4 weeks, followed by an additional 20 weeks of follow-up after treatment.

Fatigue severity, the primary outcome, was assessed via questionnaire at 4 and 24 weeks. The secondary outcomes of level of impairment, physical and social functioning, psychological distress, and pain severity were assessed at 4 and 24 weeks. The researchers found no clinically meaningful difference in fatigue severity with anakinra. They also found no statistically significant differences between groups for secondary outcomes. They conclude that if IL-1 plays a role in CFS, blocking it with anakinra has no effect.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the author, Megan Roerink, MD, please contact

2. Disrupting the flow of international medical graduates to the U.S. will have a negative effect on patient care
Abstract: URL goes live when the embargo lifts

A commentary published in Annals of Internal Medicine suggests that disrupting the flow of international medical graduates who come to the United States to complete their training will have a negative impact on patient care.

Currently, internationally educated physicians account for approximately one quarter of the practicing physician workforce in the U.S. They come to the U.S. for many reasons, including the desire to engage in care that, based on their home country resource constraints, is not available. While international medical graduates enter many different medical specialties, internal medicine is by far the most common. Over the past decade, there have been calls for the U.S. to train its own physicians and stop relying on economically underdeveloped nations to augment the workforce. However, there is no clear path to self-sufficiency. International graduates are needed to fill practice gaps left by U.S. graduates who may not choose careers in certain specialties or practice in undeserved areas.

In his commentary, William W. Pinsky, MD, President and CEO of the Educational Commission for Foreign Medical Graduates (ECFMG), located in Philadelphia, describes the current vetting process for international medical graduates and outlines their importance to quality healthcare delivery in the U.S. and the subsequent contribution to the safety of the country.

Note: For an embargoed PDF, please contact Cara Graeff. To interview the author, William Pinsky, MD, please contact Liz Ingram at or 215-823-2108.
Also new in this issue:

Developing Recommendations for Evidence-Based Clinical Preventive Services for Diverse Populations: methods of the U.S. Preventive Services Task Force

Kirsten Bibbins-Domingo, PhD, MD, MAS; Evelyn Whitlock, MD, MPH; Tracy Wolff, MD, MPH; Quyen Ngo-Metzger, MD, MPH; William R. Phillips, MD, MPH; Karina W. Davidson, PhD, MASc; Alex H. Krist, MD, MPH; Jennifer S. Lin, MD, MCR; Carol M. Mangione, MD, MSPH; Ann E. Kurth, PhD, CNM, MSN, MPH; Francisco A.R. Garc?´a, MD, MPH; Susan J. Curry, PhD; David C. Grossman, MD, MPH; C. Seth Landefeld, MD; John W. Epling Jr., MD, MSEd; and Albert L. Siu, MD, MSPH

Research and Reporting Methods


American College of Physicians

Related Chronic Fatigue Syndrome Articles:

Chronic fatigue syndrome linked to imbalanced microbiome
Scientists at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health have discovered abnormal levels of specific gut bacteria related to chronic fatigue syndrome/myalgic encephalomyelitis, or ME/CFS, in patients with and without concurrent irritable bowel syndrome, or IBS.
Scientists discover biological evidence of 'atypical' chronic fatigue syndrome
Scientists at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health are the first to report immune signatures differentiating two subgroups of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): 'classical' and 'atypical.' This complex, debilitating disease is characterized by symptoms ranging from extreme fatigue after exertion to difficulty concentrating, headaches, and muscle pain.
Anakinra does not seem to improve fatigue severity in women with chronic fatigue syndrome
The anti-inflammatory biologic drug anakinra does not seem to reduce fatigue severity in women with chronic fatigue syndrome.
International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis hosts conference
Chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), a mysterious, debilitating and misunderstood disease that affects an estimated 1 million Americans, will be the focus of an international conference on Oct.
Management of fatigue and sleep in chronic illness
The College of Nursing at the University of Massachusetts Amherst recently was awarded a five-year, $1.23 million grant from the National Institute of Nursing Research to create a new center where scientists will develop technologies to help people with chronic illness manage fatigue and impaired sleep.
Researchers identify characteristic chemical signature for chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a mysterious and maddening condition, with no cure or known cause.
Chronic fatigue syndrome flare-ups caused by straining muscles and nerves
Mild to moderate muscle and nerve strain provokes symptom flares in individuals with chronic fatigue syndrome.
Chronic fatigue syndrome is in your gut, not your head
Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest.
NIAID funding to Jackson Laboratory researcher to investigate chronic fatigue syndrome
Professor Derya Unutmaz, M.D., of The Jackson Laboratory for Genomic Medicine, will receive five years of funding -- totaling $3,281,515 from the National Institute of Allergy and Infectious Diseases -- to find better ways to diagnose and treat myalgic encephalomyelitis, the debilitating and mysterious condition more generally known as chronic fatigue syndrome.
Chronic fatigue patients more likely to suppress emotions
Chronic fatigue syndrome patients report they are more anxious and distressed than people who don't have the condition, and they are also more likely to suppress those emotions.

Related Chronic Fatigue Syndrome Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".